Corporate venturing unit Shire Strategic Investment has led the latest investment in biotech company Promedior. They close their D round at $24.5m
Promedior, a US-based biotech company developing therapeutics for the treatment of fibrosis, has closed its Series D round at $24.5m, having just added a $3m investment from corporate venture capital firm Shire Strategic Investment Group. Promedior received $21.5m in July of this year led by Fibrotic Ventures. Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital were also involved.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat fibrotic diseases. Promedior…